Please ensure Javascript is enabled for purposes of website accessibility

3 Top Dividend Stocks to Buy Right Now

By Keith Speights - Feb 7, 2021 at 6:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These stocks offer great dividends and more.

Investing in dividend stocks boils down to two steps. First, find stocks that pay attractive dividends. Second, eliminate any stocks lacking the strong underlying businesses needed to ensure the dividends keep coming. It's really that simple.

The main drawback to that two-part method is that you'll still have a lot of stocks from which to choose. How do you whittle down the list? That's where other considerations come into play, such as track records of dividend increases and growth prospects. 

Your ideal candidates will check off all the boxes. Here are three top dividend stocks to buy right now that achieve that goal.

"Dividends" written on a sticky note next to a roll of $100 bills, a calculator, a marker, and a book

Image source: Getty Images.

1. AbbVie

If you're looking for an attractive dividend stock, AbbVie (ABBV -1.97%) should be really high on your list. Its dividend yield currently stands at 4.9%. The big drugmaker has increased its dividend for 49 consecutive years, qualifying it as a Dividend Aristocrat (S&P 500 members that have at least 25 years in a row of dividend hikes). 

Can AbbVie keep its streak of dividend increases going? The company's top-selling drug, Humira, faces biosimilar competition in the U.S. beginning in 2023. That almost certainly means the drug's sales will sink and negatively impact AbbVie's finances.

However, dividend-seeking investors shouldn't have anything to worry about. The company already markets two autoimmune disease drugs poised to take the baton from Humira. AbbVie expects Rinvoq and Skyrizi will generate combined sales of $15 billion by 2025. Its lineup also includes other products with strong momentum, such as blood cancer drugs Imbruvica and Venclexta.

AbbVie's sales growth should be robust in 2021 and 2022. The company expects that its total revenue will decline in 2023. However, AbbVie thinks it will quickly return to revenue growth in subsequent years.

2. Brookfield Infrastructure Partners

I suspect you'll also like Brookfield Infrastructure Partners' (BIP 1.42%) dividend yield of 3.7%. The company isn't a Dividend Aristocrat like AbbVie because it's only been in business since 2008 and isn't a member of the S&P 500. However, Brookfield Infrastructure's dividend track record is a good one, with a 10% compound annual growth rate for its distribution.

Brookfield Infrastructure runs the kind of businesses that are ideal for generating steady income. Its assets include cell towers, data centers, natural gas pipelines, ports, railroads, and toll roads. 

Economic recessions and pandemics don't affect Brookfield Infrastructure all that much. Around 70% of its business is pretty well insulated from macroeconomic disruptions. The company's diversification and long-term contracts help provide a nice safety cushion.

Brookfield Infrastructure's management refers to the company as a "grow-tility." The company is similar to a utility (most of its business consists of utilities). However, it also delivers solid double-digit growth.

3. Innovative Industrial Properties

At first glance, Innovative Industrial Properties' (IIPR -1.69%) dividend yield of 2.4% might not seem all that great, but I think that IIP is actually a dividend investor's dream

First of all, the dividend yield isn't nearly as high it would otherwise be because IIP stock has skyrocketed nearly 700% over the last three years. During the same period, the company's dividend payout nearly quadrupled. 

IIP continues to benefit from the boom in the U.S. marijuana market. The company buys properties from medical cannabis operators, then leases the properties back to them. These sale-leaseback deals give IIP steady recurring revenue that continues for years.

The company currently owns 67 properties in 17 states. It should have plenty of room to continue expanding in these states. There are also another 18 states where medical cannabis is legal that IIP could potentially move into down the road. A fast-growing dividend and solid growth prospects make IIP a great dividend stock to buy right now.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Innovative Industrial Properties Stock Quote
Innovative Industrial Properties
IIPR
$128.99 (-1.69%) $-2.22
Brookfield Infrastructure Partners L.P. Stock Quote
Brookfield Infrastructure Partners L.P.
BIP
$62.07 (1.42%) $0.87
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$148.03 (-1.97%) $-2.98

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.